You are invited to attend the exclusive Decision Resources Pharmaview competitive assessment entitled Pfizer Adds to Its Pain Franchise and Further Diversifies Its Business with Accretive Financial Deal for King
. This session is ONLY available to Pharmaview subscribers.
Recorded live on Friday, October 22, 2010
One year after the closing of the Wyeth mega-merger, Pfizer is back in the hunt for new acquisitions, with a surprising deal for the troubled King Pharmaceuticals. Although King is struggling through the generic erosion of its leading Skelaxin franchise, Pfizer has made a tender offer at a 40 percent premium ($14.25 a share), valuing the company at $3.3B (net of cash). Why is Pfizer willing to make this investment in King, when its own business is on the verge of the biggest patent expiration in the industry’s history? What does Pfizer expect to gain from King’s business and will it help them manage through the upcoming Lipitor patent expiration?
Decision Resources’ Pharmaview Analyst Mike Latwis breaks down what this combination means to the pain franchise and future growth outlook for Pfizer.
In this 20 minute presentation, Mr. Latwis will answer the following questions:
- Why is Pfizer interested in King’s business, which has been in decline throughout 2010?
- How will this deal impact Pfizer’s pain franchise? What are the major opportunities and risks in King’s portfolio and pipeline?
- What impact will the addition of King have on Pfizer’s ability to manage through the Lipitor patent expiration?
- How does King’s business fit into Pfizer’s overall corporate strategy?
- How does this deal help position Pfizer’s business for future growth?
to learn how you can purchase this service and access a recorded playback of this event.
to view the invite.